Candel Therapeutics announces CAN-2409 achieved primary endpoint

Candel Therapeutics (CADL) announced results from a multicenter phase 3 clinical trial evaluating CAN-2409 viral immunotherapy in localized prostate cancer patients. The study met its primary endpoint, demonstrating a statistically significant improvement in disease-free survival compared to the control arm. Key topline results include: Statistically significant improvement in DFS for CAN-2409 plus radiation therapy vs. radiation therapy alone in the intent to treat population; 14.5% relative improvement in DFS observed at 54 months for the CAN-2409 treatment arm compared to the placebo control arm; DFS improvement was observed both in patients receiving short term ADT and in patients not receiving ADT; In an analysis that focused on prostate-specific outcomes, CAN-2409 showed a highly significant effect on prostate cancer-free survival; Significant increase in the proportion of patients achieving a prostate-specific antigen nadir was observed in the treatment arm compared to the placebo control arm; CAN-2409 induced 80.4% pathological complete responses (pCRs) in the 2-year post-treatment biopsies compared to 63.6% observed in the control arm